表紙
市場調査レポート

世界の肝臓癌治療市場:他の製品が治験の最終段階で失敗したのに伴い、Nexavarが重症患者向けの唯一認可された標的療法として市場を押さえ続ける

Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail

発行 GBI Research 商品コード 258791
出版日 ページ情報 英文 72 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.69円で換算しております。
Back to Top
世界の肝臓癌治療市場:他の製品が治験の最終段階で失敗したのに伴い、Nexavarが重症患者向けの唯一認可された標的療法として市場を押さえ続ける Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail
出版日: 2012年12月31日 ページ情報: 英文 72 Pages
概要

世界の先進7ヶ国(米国・フランス・ドイツ・イタリア・スペイン・英国・日本)の肝臓癌治療の関連市場は、2011年に3億7430万米ドルの規模に達しました。また、2004年以来の年平均(CAGR)成長率は21.7%と推計されています。また、2011〜2018年の年平均(CAGR)市場成長率は8.1%、2018年の市場規模は6億4430万米ドルと推計されています。

当レポートでは、米国・欧州主要5ヶ国(フランス・ドイツ・イタリア・スペイン・英国)・日本における肝臓がん治療の関連市場について分析し、市場の特徴・構造や、全体的な市場動向(過去・今後7年間分)、地域別の詳細動向、治験の進行状況、主要企業のプロファイル、資本取引動向などを調査・推計して、その結果を概略以下の内容でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 市場概要

  • イントロダクション
    • 良性腫瘍
    • 原発性肝癌
    • 二次肝癌
  • 症状
  • 診断
    • 検査室での検査
    • 画像検査
    • その他
  • 治療オプション
    • 手術
    • 非手術的治療法
    • 治療の一般的な流れ
    • ステージ別の治療法
    • 新しい治療技術

第4章 市場の特徴と予測

  • 市場収益
  • 年間治療費
  • 市販製品
    • Nexavar
    • Miripla
  • 治療法の利用パターン
    • 罹患人口
    • 診断済み人口
    • 治療済み人口
  • 市場促進・阻害要因
    • 市場促成要因
    • 市場阻害要因

第5章 各地域の市場環境

  • 米国
    • イントロダクション
    • 市場収益
    • 治療費
    • 治療法の利用パターン
  • 欧州主要5ヶ国
    • イントロダクション
    • 市場収益
    • 治療費
    • 治療法の利用パターン
  • 日本
    • イントロダクション
    • 市場収益
    • 治療費
    • 治療法の利用パターン

第6章 パイプライン分析

  • イントロダクション
  • 研究開発(R&D)製品パイプライン:開発段階別
    • フェーズIII
    • フェーズII/III
    • フェーズII
    • フェーズI/II
    • フェーズI
    • 前臨床
    • 創薬
  • 有望な分子のプロファイル
    • PrevOnco
    • Ramucirumab
    • ThermoDox
    • Afinitor

第7章 競争環境

  • Bayer
  • 大日本住友製薬

第8章 戦略的企業統合

  • イントロダクション
  • 地域別動向
  • 年度別動向
  • 企業合併・買収(M&A)取引
    • 概要
    • 主な企業合併・買収(M&A)取引のプロファイル
  • ライセンス契約
    • 概要
    • 主なライセンス契約のプロファイル
  • 共同開発契約
    • 概要
    • 主な共同開発契約のプロファイル

第9章 付録

図表一覧

目次
Product Code: GBIHC287MR

Summary

Leading business intelligence provider, GBI Research, has released its latest research report, entitled: "Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail". The report provides insights into the liver cancer therapeutics market in the US, the top five European countries (the UK, Germany, France, Italy and Spain) and Japan, with market forecasts until 2018. It provides in-depth analysis of the major marketed products, as well as insights into the liver cancer therapeutics R&D pipeline. The report also gives in-depth analysis of the unmet needs, drivers and barriers that affect the markets in these countries. Additionally, it discusses the global pipeline for all the liver cancer molecules across various stages of development.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research found that the liver cancer therapeutics in the top seven markets (the US, the UK, Germany, France, Spain, Italy and Japan) was estimated at $374.3m in 2011, having grown at a Compound Annual Growth Rate (CAGR) of 21.7% from 2004. Growth was driven by an increase in the patient volume and the Annual Cost of Therapy (ACT) per patient, which increased due to the approval of Nexavar (sorafenib) in the US and Europe. The market is forecast to reach revenues of $644.3m by 2018, growing at a CAGR of 8.1% from 2011.

The current competition in the liver cancer market is weak, as Nexavar is the only drug approved for advanced Hepatocellular Carcinoma (HCC) with the exception of Miripla (miriplatin) in Japan. However, there are some molecules in Phase III development as first-line and second-line treatments which promise to influence the competitive landscape in the next two to three years. The anticipated launch of Eli Lilly's ramucirumab (IMC-1121B), a monoclonal antibody in 2014; Celsion Corporation's ThermoDox in 2014; and PrevOnco in 2015 will drive the market forward.

Scope

  • Annualized market data for the liver cancer therapeutics market from 2004 to 2011 and forecast to 2018
  • Analysis of the liver cancer therapeutics market in the leading geographies of the world: the US, the UK, Germany, France, Italy, Spain, and Japan
  • Market characterization of the liver cancer therapeutics market including market size, annual cost of therapy and treatment usage patterns
  • Key drivers and barriers that affect the market
  • Coverage of pipeline molecules in various Phases of drug development
  • Competitive benchmarking of leading companies including Bayer and Dainippon Sumitomo Pharma
  • Key M&A activities and licensing agreements that have taken place between 2008 and October 2012 in liver cancer therapeutics in the top seven markets

Reasons to buy

  • Align your product portfolio to the markets with high growth potential
  • Develop market-entry and market-expansion strategies by identifying the regions and market segments poised for strong growth
  • Create a more tailored country strategy through the understanding of key drivers and barriers of the liver cancer therapeutics market
  • Develop key strategic initiatives by understanding the key focus areas and top-selling products of leading companies
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Liver Cancer Therapeutics Market to 2018-Introduction

3. Liver Cancer Therapeutics Market to 2018-Overview

  • 3.1. Introduction
    • 3.1.1. Benign Tumor
    • 3.1.2. Primary Liver Cancer
    • 3.1.3. Secondary Liver Cancer
  • 3.2. Symptoms
  • 3.3. Diagnosis
    • 3.3.1. Laboratory Tests
    • 3.3.2. Imaging Tests
    • 3.3.3. Others
  • 3.4. Treatment Options
    • 3.4.1. Surgery
    • 3.4.2. Non-surgical
    • 3.4.3. General Treatment Algorithm
    • 3.4.4. Treatment by Stage
    • 3.4.5. New Technologies in Treatment

4. Liver Cancer Therapeutics Market to 2018-Market Characterization and Forecasts

  • 4.1. Revenue
  • 4.2. Annual Cost of Therapy
  • 4.3. Marketed Products
    • 4.3.1. Nexavar
    • 4.3.2. Miripla
  • 4.4. Treatment Usage Pattern
    • 4.4.1. Prevalence Population
    • 4.4.2. Diagnosed Population
    • 4.4.3. Prescription Population
  • 4.5. Drivers and Barriers of Liver Cancer Therapeutics Market
    • 4.5.1. Drivers
    • 4.5.2. Barriers

5. Liver Cancer Therapeutics Market to 2018-Geographical Landscape

  • 5.1. US
    • 5.1.1. Introduction
    • 5.1.2. Revenue
    • 5.1.3. Cost of Therapy
    • 5.1.4. Treatment Usage Pattern
  • 5.2. Top Five European Countries
    • 5.2.1. Introduction
    • 5.2.2. Revenue
    • 5.2.3. Cost of Therapy
    • 5.2.4. Treatment Usage Pattern
  • 5.3. Japan
    • 5.3.1. Introduction
    • 5.3.2. Revenue
    • 5.3.3. Cost of Therapy
    • 5.3.4. Treatment Usage Pattern

6. Liver Cancer Therapeutics Market to 2018-Pipeline Analysis

  • 6.1. Introduction
  • 6.2. R&D Product Pipeline by Stage of Development
    • 6.2.1. Phase III
    • 6.2.2. Phase II/III
    • 6.2.3. Phase II
    • 6.2.4. Phase I/II
    • 6.2.5. Phase I
    • 6.2.6. Pre-Clinical
    • 6.2.7. Discovery
  • 6.3. Profiles of Promising Molecules
    • 6.3.1. PrevOnco
    • 6.3.2. Ramucirumab
    • 6.3.3. ThermoDox
    • 6.3.4. Afinitor

7. Liver Cancer Therapeutics Market to 2018-Competitive Landscape

  • 7.1. Bayer
  • 7.2. Dainippon Sumitomo Pharma

8. Liver Cancer Therapeutics Market to 2018-Strategic Consolidations

  • 8.1. Introduction
  • 8.2. Deals by Geography
  • 8.3. Deals by Year
  • 8.4. Mergers and Acquisition Deals
    • 8.4.1. Overview
    • 8.4.2. Profiles of Major M&A Deals
  • 8.5. Licensing Agreements
    • 8.5.1. Overview
    • 8.5.2. Profiles of Major Licensing Agreements
  • 8.6. Co-Development Agreements
    • 8.6.1. Overview
    • 8.6.2. Profiles of Major Co-Development Agreements

9. Liver Cancer Therapeutics Market to 2018-Appendix

  • 9.1. Market Definitions
  • 9.2. Abbreviations
  • 9.3. Bibliography
  • 9.4. Research Methodology
    • 9.4.1. Coverage
    • 9.4.2. Secondary Research
    • 9.4.3. Primary Research
  • 9.5. Therapeutic Landscape
    • 9.5.2. Market Size by Geography
  • 9.6. Geographical Landscape
  • 9.7. Pipeline Analysis
  • 9.8. Competitive Landscape
    • 9.8.1. Expert Panel Validation
  • 9.9. Contact Us
  • 9.10. Disclaimer

List of Tables

  • Table 1: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue ($m), 2004-2011
  • Table 2: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts ($m), 2011-2018
  • Table 3: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue by Geography ($m), 2004-2011
  • Table 4: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts by Geography ($m), 2011-2018
  • Table 5: Liver Cancer Therapeutics Market, Top Seven Markets, Annual Cost of Therapy ($), 2004-2011
  • Table 6: Liver Cancer Therapeutics Market, Top Seven Markets, Annual Cost of Therapy ($), 2011-2018
  • Table 7: Liver Cancer Therapeutics Market to 2018, Nexavar, Clinical Trial Results
  • Table 8: Liver Cancer Therapeutics Market, Nexavar, Adverse Reactions Reported in Clinical Trial
  • Table 9: Liver Cancer Therapeutics Market, Nexavar, Approval History
  • Table 10: Liver Cancer Therapeutics Market, Top Seven Markets, Treatment Usage Pattern ('000), 2004-2011
  • Table 11: Liver Cancer Therapeutics Market, Top Seven Markets, Treatment Usage Pattern ('000), 2011-2018
  • Table 12: Liver Cancer Therapeutics Market, US, Revenue ($m), 2004-2011
  • Table 13: Liver Cancer Therapeutics Market, US, Revenue Forecasts ($m), 2011-2018
  • Table 14: Liver Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2004-2011
  • Table 15: Liver Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2011-2018
  • Table 16: Liver Cancer Therapeutics Market, US, Treatment Usage Pattern ('000), 2004-2011
  • Table 17: Liver Cancer Therapeutics Market, US, Treatment Usage Pattern ('000), 2011-2018
  • Table 18: Liver Cancer Therapeutics Market, Top Five European Countries, Revenue ($m), 2004-2011
  • Table 19: Liver Cancer Therapeutics Market, Top Five European Countries, Revenue Forecast ($m), 2011-2018
  • Table 20: Liver Cancer Therapeutics Market to 2018, Top Five European Countries, Annual Cost of Therapy ($), 2004-2011
  • Table 21: Liver Cancer Therapeutics Market to 2018, Top Five European Countries, Annual Cost of Therapy ($), 2011-2018
  • Table 22: Liver Cancer Therapeutics Market, Top Five European Countries, Treatment Usage Pattern ('000), 2004-2011
  • Table 23: Liver Cancer Therapeutics Market, Top Five European Countries, Treatment Usage Pattern ('000), 2011-2018
  • Table 24: Liver Cancer Therapeutics Market, Japan, Revenue ($m), 2004-2011
  • Table 25: Liver Cancer Therapeutics Market, Japan, Revenue Forecast ($m), 2011-2018
  • Table 26: Liver Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2004-2011
  • Table 27: Liver Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011-2018
  • Table 28: Liver Cancer Therapeutics Market, Japan, Treatment Usage Pattern ('000), 2004-2011
  • Table 29: Liver Cancer Therapeutics Market, Japan, Treatment Usage Pattern ('000), 2011-2018
  • Table 30: Liver Cancer Therapeutics Market, Global, Pipeline Products, by Stage of Development, 2012
  • Table 31: Liver Cancer Therapeutics Market, Global, Phase III Pipeline
  • Table 32: Liver Cancer Therapeutics Market, Global, Phase II/III Pipeline
  • Table 33: Liver Cancer Therapeutics Market, Global, Phase II Pipeline
  • Table 34: Liver Cancer Therapeutics Market, Global, Phase I/II Pipeline
  • Table 35: Liver Cancer Therapeutics Market, Global, Phase I Pipeline
  • Table 36: Liver Cancer Therapeutics Market, Global, Preclinical, 2012
  • Table 37: Liver Cancer Therapeutics Market, Global, Discovery, 2012
  • Table 38: Liver Cancer Therapeutics Market, Global, Bayer AG, Pharmaceutical Brands, 2012
  • Table 39: Liver Cancer Therapeutics Market, Global, Dainippon Sumitomo Pharma, Pharmaceutical Brands, 2012
  • Table 40: Liver Cancer Therapeutics Market, Global, Deals by Type of Agreement, 2007-2012
  • Table 41: Liver Cancer Therapeutics Market, Global, Deals by Geography, 2007-2012
  • Table 42: Liver Cancer Therapeutics Market, Global, Deals by Year, 2007-2012
  • Table 43: Liver Cancer Therapeutics Market, Global, Major M&A Deals, 2007-2012
  • Table 44: Liver Cancer Therapeutics Market, Global, Major Licensing Agreement Deals, 2007-2012
  • Table 45: Liver Cancer Therapeutics Market, Global, Major Co-Development Deals, 2007-2012

List of Figures

  • Figure 1: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, Treatment Options, 2012
  • Figure 2: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, General Treatment Algorithm
  • Figure 3: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, Stage I and II, Treatment Algorithm
  • Figure 4: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, Stage III and IV, Treatment Algorithm
  • Figure 5: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts ($m), 2004-2018
  • Figure 6: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts by Geography ($m), 2004-2018
  • Figure 7: Liver Cancer Therapeutics Market, Top Seven Markets, Annual Cost of Therapy ($), 2004-2018
  • Figure 8: Liver Cancer Therapeutics Market, Top Seven Markets, Treatment Usage Pattern ('000), 2004-2018
  • Figure 9: Liver Cancer Therapeutics Market, Top Seven Markets, Drivers and Barriers, 2012
  • Figure 10: Liver Cancer Therapeutics Market, US, Revenue Forecasts ($m), 2004-2018
  • Figure 11: Liver Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2004-2018
  • Figure 12: Liver Cancer Therapeutics Market, US, Treatment Usage Pattern ('000), 2004-2018
  • Figure 13: Liver Cancer Therapeutics Market, Top Five European Countries, Revenue Forecast ($m), 2004-2018
  • Figure 14: Liver Cancer Therapeutics Market, Top Five European Countries, Market Revenue ($m), 2004-2018
  • Figure 15: Liver Cancer Therapeutics Market, Top Five European Countries, Annual Cost of Therapy ($), 2004-2018
  • Figure 16: Liver Cancer Therapeutics Market, Top Five European Countries, Treatment Usage Pattern ('000), 2004-2018
  • Figure 17: Liver Cancer Therapeutics Market, Japan, Revenue Forecast ($m), 2004-2018
  • Figure 18: Liver Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2004-2018
  • Figure 19: Liver Cancer Therapeutics Market, Japan, Treatment Usage Pattern ('000), 2004-2018
  • Figure 20: Liver Cancer Therapeutics Market, Global, Pipeline Products, by Stage of Development, 2012
  • Figure 21: Liver Cancer Therapeutics Market, Global, Deals by Type of Agreement, 2007-2012
  • Figure 22: Liver Cancer Therapeutics Market, Global, Deals by Geography, 2007-2012
  • Figure 23: Liver Cancer Therapeutics Market, Global, Deals by Year, 2007-2012
  • Figure 24: GBI Research Market Forecasting Model
Back to Top